Abstract PO2-13-12: Serum Thioredoxin 1 Enhances Breast Cancer Detection in Mammography and Breast Ultrasound, Including Dense Breasts

Abstract

Abstract Background: Breast cancer (BC), when detected in its early stages, generally carries a more favorable prognosis than other types of cancer. Currently, the screening and early detection of breast cancer rely predominantly on image-oriented diagnostic methods. However, these methods inherently fall short in capturing the dynamic nature of cancer cells. Mammography has known limitations in clinical sensitivity, particularly in cases with high breast density. While breast ultrasound can mitigate some of these limitations, there remain unmet needs in this field. Previously, we reported the promising clinical performance (Sensitivity: 96.43%, Specificity: 97.32%) of serum thioredoxin 1 (Trx1) as a potential novel means for detecting breast cancer. In this study, we aim to evaluate the extent to which serum Trx1 can enhance the accuracy of breast cancer diagnosis, including in dense breasts, within the imaging-based diagnostic system powered by mammography and ultrasonography. Methods: We have generated monoclonal antibodies against Trx1 and developed an ELISA kit (DxMe® BC Kit, E&S Healthcare, Korea) that quantifies Trx1 in serum. A total of 308 biopsy-confirmed breast cancer patients, who had undergone mammography prior to their final diagnosis, were recruited. The clinical information of these 308 patients was retrospectively examined and collected. The data from 254 individuals, who also had results from breast ultrasound, and 261 individuals, who had records of breast density, were analyzed collectively. Freshly collected blood was prepared as previously indicated, and then tested with the kit to determine the level of Trx1. All serum samples were measured twice, and statistical analyses were conducted using ROC analysis, one-way ANOVA, and unpaired t-tests. Results: Clinical sensitivity for BC detection was analyzed using the Trx1 levels of the 254 subjects who underwent both mammography and breast ultrasound. The respective sensitivities of mammography, breast ultrasound, and the DxMe® BC Kit were 72.83%, 92.91%, and 96.46%. With combined analysis of mammography, breast ultrasound, and Trx1, the sensitivity increased to 98.43% for mammography + breast ultrasound, and 98.82% for mammography + Trx1. When breast ultrasound + Trx1 was considered, the sensitivity rose to 99.61%. Likewise, the sensitivity of mammography + breast ultrasound + Trx1 was also measured at 99.61%. Among the 261 breast cancer patients with available information about breast density, 186 patients (71.3%) had dense breasts. The clinical sensitivity of mammography and Trx1 was specifically analyzed for these dense breast cases. Mammography demonstrated a sensitivity of 64.3%, while the DxMe® BC kit exhibited a sensitivity of 97.2%. When mammography and Trx1 were analyzed in parallel, sensitivity increased to 99.7%. Conclusion: This study demonstrated that the DxMe® BC kit, which quantifies serum Trx1 levels, can enhance the accuracy of conventional image-based diagnostics for breast cancer screening and early detection by more than 25%. This improvement in sensitivity was observed when mammography and breast ultrasound were each used in conjunction with Trx1, with no significant difference noted between these two combinations. Notably, in the case of dense breasts, the Trx1 test improved sensitivity by more than 30% compared to mammography. Given that sensitivity increases when mammography and Trx1 tests are used together, it showed that incorporating the Trx1 test alongside traditional mammography could significantly enhance diagnostic performance in dense breasts up to 35%. This approach has the potential to streamline the breast cancer diagnostic process, reduce time and cost, and improve the reliability of current breast cancer screening and early detection methods, regardless of breast density. Citation Format: Young Kim, Hyemi Ko, Yeri Lee, Keunkoo Shin, Jongam Song, Jeryoung Kim, Kyounghoon Suh, Jinsun Lee. Serum Thioredoxin 1 Enhances Breast Cancer Detection in Mammography and Breast Ultrasound, Including Dense Breasts [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-13-12.